While the basic principles of personalized medicine and pharmacogenomics has been covered by numerous texts, there are none to date that focuses on the specific tests themselves that are in current clinical practice and those that are being proposed for implementation in the near future. Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory focuses almost entirely on the specifics of each test that is needed to implement these tests into a clinical laboratory. This volume presents the first compilation of the tests currently in routine clinical use. The chapter authors of this unique and invaluable title comprise a range of renowned authorities and investigators who have conducted the essential clinical trials necessary to justify pharmacogenomic testing today. The book is divided into four parts: Basic Concepts, Specific Pharmacogenomic Targets, Drugs that Cause Delayed Hypersensitivity, and Miscellaneous Drugs. Each author provides a pharmacologic background on the target drug, the need for pharmacogenomic testing, and how results can be translated into clinical decisions. Where appropriate, case studies are given to illustrate typical clinical scenarios. An extensive bibliography is provided so that the reader can refer to the original studies. This well-designed resource will appeal to clinical laboratory directors who are contemplating or assigned the task of establishing a pharmacogenomics laboratory and a wide range of clinicians who must interpret results of testing. Focused and immensely useful, Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory is a timely and outstanding contribution to the literature and will be instrumental in defining this rapidly growing field.
Inhaltsverzeichnis
Part 1. Basic concepts Chapter 1. Issues in Translation of Pharmacogenomics into Clinical Practice. Kiang-Teck J. Yeo, Nikolina Babic, Alan H. B. WuChapter 2. Molecular Diagnostic Methods in Pharmacogenomics Nikolina Babic*, Loren J. Joseph, Kiang-Teck J. YeoChapter 3. Economics of pharmacogenomic testing in clinical practice Alan H. B. WuChapter 4. From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice SystemSteven H. Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H. B. Wu, Kiang-Teck J. Yeo. Part 2. Specific pharmacogenomic targets: ChemotherapeuticsChapter 5. IrinotecanR. Stephanie Huang, Federico Innocenti and Mark J. RatainChapter 6. Pharmacogenomics of tamoxifen Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman Chapter 7. ThiopurinesTerreia S. Jones, Mary V. Relling Part 3. Specific pharmacogenomic targets: Cardiovascular drugsChapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation DrugsCharles EbyChapter 9. Clopidogrel and SalicylatesJanice Y Chyou, Marc S SabatineChapter 10. DNA-Guided Statin TherapyGualberto Ruaño, Richard L. Seip, Jorge DucongeChapter 11. The statin response gene: Kif6. . . . . . . . . . . . . . . . . . . . . . . H. Robert Superko, Tom White, James Forrester, Spencer King III. Part 4. Drugs that cause delayed hypersensitivityChapter 12. AbacavirElizabeth J. Phillips, Simon A. MallalChapter 13. AllopurinolPei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong ChenChapter 14. Carbamazepine and its structurally-related antiepileticsShuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong ChenPart 5. . . . . . . . Miscellaneous drugsChapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/InjuryHong-Kee Lee, Lionel D. LewisChapter 16. Immunosuppressants Pharmacogenomics Ping WangSteven H. Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H. B. Wu, Kiang-Teck J. Yeo. Part 2. Specific pharmacogenomic targets: ChemotherapeuticsChapter 5. IrinotecanR. Stephanie Huang, Federico Innocenti and Mark J. RatainChapter 6. Pharmacogenomics of tamoxifen Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman Chapter 7. ThiopurinesTerreia S. Jones, Mary V. Relling Part 3. Specific pharmacogenomic targets: Cardiovascular drugsChapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation DrugsCharles EbyChapter 9. Clopidogrel and SalicylatesJanice Y Chyou, Marc S SabatineChapter 10. DNA-Guided Statin TherapyGualberto Ruaño, Richard L. Seip, Jorge DucongeChapter 11. The statin response gene: Kif6. . . . . . . . . . . . . . . . . . . . . . . H. Robert Superko, Tom White, James Forrester, Spencer King III. Part 4. Drugs that cause delayed hypersensitivityChapter12. AbacavirElizabeth J. Phillips, Simon A. MallalChapter 13. AllopurinolPei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong ChenChapter 14. Carbamazepine and its structurally-related antiepileticsShuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong ChenPart 5. . . . . . . . Miscellaneous drugsChapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/InjuryHong-Kee Lee, Lionel D. LewisChapter 16. Immunosuppressants Pharmacogenomics Ping WangChapter 14. Carbamazepine and its structurally-related antiepileticsShuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong ChenPart 5. . . . . . . . Miscellaneous drugsChapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/InjuryHong-Kee Lee, Lionel D. LewisChapter 16. Immunosuppressants Pharmacogenomics Ping Wang
